Compare Eli Lilly And Co (LLY) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Prospect Capital Corporation — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Prospect Capital Corporation trades at $1.72 (market cap $974.22M). The key difference: Eli Lilly And Co is far larger — about 1067.5× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (23.01%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Prospect Capital Corporation for 78 Days on average.
| LLY | PSEC | |
|---|---|---|
Market Cap | $1.04T | $974.22M |
Volume | 3,064,878 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $1.28K | $3.05 |
52-Week Low | $799.57 | $1.72 |
Typical Hold Time | 93 Days | 78 Days |
Enterprise Value | $1.09T | $2.73B |
Dividend Yield | 0.59% | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
PSEC trades at $1.82, down 1.09% on the day, with a bearish technical signal from moving averages. The company reported negative revenue and net income for 2025, though it has beaten EPS estimates in recent quarters. Recent news highlights dividend declarations and management commentary on the firm's track record.
The outlook is clouded by financial volatility and a mixed analyst consensus. The primary opportunity is the high dividend yield, but risks include persistent negative profitability, portfolio contraction, and a majority of analysts rating the stock as Hold or Sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
